Home >> Healthcare >> Food & Beverage >>

Global Dyslipidemia Drugs Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023

Published: Oct-2018 | Format: PDF | Global Info Research | Number of pages: 149 | Code: MRS - 355466

Lipid refers to fat comprising proteins and carbohydrates. Cholesterol and triglycerides are lipids that are stored in the human body and serve as a source of energy. Dyslipidaemia is the imbalance in the lipid level in the bloodstream. It is characterized by high levels of total cholesterol and low-density lipoprotein cholesterol (LDL-C) in the blood. High cholesterol levels can cause cardiovascular diseases (CVD) such as stroke and atherosclerosis. The typical range of total blood cholesterol is 140-200 mg/dL. Blood cholesterol contains individual components such as LDL-C and high-density lipoprotein cholesterol (HDL-C). Low-density lipoprotein (LDL) carries cholesterol to the body while high-density lipoprotein (HDL) removes cholesterol from the cells by reversing cholesterol transport to the liver. Due to their distinct roles, these components are individually assessed to determine the dyslipidemic status of an individual. 



Scope of the Report:

This report focuses on the Dyslipidemia Drugs in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

The increasing risk of cardiovascular disease (CVDs) is the primary driver for the market’s growth. Elevated cholesterol levels account for nearly one-third of the total ischemic heart diseases and persist as a substantial cause of ischemic heart diseases and strokes in emerging countries such as India and China. Thus, the cardiovascular risk management guidelines set by authorities such as the American College of Cardiology and American Heart Association acknowledge the decreasing the blood cholesterol as a prime factor in cutting down on the cardiovascular risks. This, in turn, drives the cholesterol maintaining drugs to avoid CVDs risk and boosting the sales of the drugs market.

With the presence of numerous small and larger vendors, the global dyslipidemia drugs market is largely competitive. Competition is observed from the regional players globally, and there are numerous new manufacturers entering the market. Moreover, companies like Amgen, HanAll BioPharma, Kowa Pharmaceuticals, CJ HealthCare, Catabasis Pharmaceuticals, JW Pharmaceuticals, and Esperion Pharmaceuticals are expected to enter the market over the next four years.

The worldwide market for Dyslipidemia Drugs is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.



Market Segment by Manufacturers, this report covers

    AstraZeneca

    Merck

    Pfizer

    Sanofi

    Alnylam Pharmaceuticals

    Amarin Corporation

    Amgen

    Bristol-Myers Squibb

    Catabasis Pharmaceuticals

    Cerenis

    Cipla

    CJ HealthCare

    CKD Bio

    Daewoong Pharmaceutical

    Daiichi Sankyo

    Eli Lilly

    Esperion Therapeutics

    GlaxoSmithKline

    JW Pharmaceuticals

    Kadmon Pharmaceuticals

    Lupin Pharmaceuticals



Market Segment by Regions, regional analysis covers

    North America (United States, Canada and Mexico)

    Europe (Germany, France, UK, Russia and Italy)

    Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

    South America (Brazil, Argentina, Colombia etc.)

    Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)



Market Segment by Type, covers

    Statins

    Cholesterol absorption inhibitors

    Dyslipidemia injectable



Market Segment by Applications, can be divided into

    Hospitals and Clinics

    Medical Laboratories

    Drug Stores

    Others



There are 15 Chapters to deeply display the global Dyslipidemia Drugs market.

Chapter 1, to describe Dyslipidemia Drugs Introduction, product scope, market overview, market opportunities, market risk, market driving force;

Chapter 2, to analyze the top manufacturers of Dyslipidemia Drugs, with sales, revenue, and price of Dyslipidemia Drugs, in 2016 and 2017;

Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;

Chapter 4, to show the global market by regions, with sales, revenue and market share of Dyslipidemia Drugs, for each region, from 2013 to 2018;

Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;

Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;

Chapter 12, Dyslipidemia Drugs market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;

Chapter 13, 14 and 15, to describe Dyslipidemia Drugs sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source

Table of Contents



1 Market Overview

    1.1 Dyslipidemia Drugs Introduction

    1.2 Market Analysis by Type

        1.2.1 Statins

        1.2.2 Cholesterol absorption inhibitors

        1.2.3 Dyslipidemia injectable

    1.3 Market Analysis by Applications

        1.3.1 Hospitals and Clinics

        1.3.2 Medical Laboratories

        1.3.3 Drug Stores

        1.3.4 Others

    1.4 Market Analysis by Regions

        1.4.1 North America (United States, Canada and Mexico)

            1.4.1.1 United States Market States and Outlook (2013-2023)

            1.4.1.2 Canada Market States and Outlook (2013-2023)

            1.4.1.3 Mexico Market States and Outlook (2013-2023)

        1.4.2 Europe (Germany, France, UK, Russia and Italy)

            1.4.2.1 Germany Market States and Outlook (2013-2023)

            1.4.2.2 France Market States and Outlook (2013-2023)

            1.4.2.3 UK Market States and Outlook (2013-2023)

            1.4.2.4 Russia Market States and Outlook (2013-2023)

            1.4.2.5 Italy Market States and Outlook (2013-2023)

        1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

            1.4.3.1 China Market States and Outlook (2013-2023)

            1.4.3.2 Japan Market States and Outlook (2013-2023)

            1.4.3.3 Korea Market States and Outlook (2013-2023)

            1.4.3.4 India Market States and Outlook (2013-2023)

            1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)

        1.4.4 South America, Middle East and Africa

            1.4.4.1 Brazil Market States and Outlook (2013-2023)

            1.4.4.2 Egypt Market States and Outlook (2013-2023)

            1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)

            1.4.4.4 South Africa Market States and Outlook (2013-2023)

            1.4.4.5 Nigeria Market States and Outlook (2013-2023)

    1.5 Market Dynamics

        1.5.1 Market Opportunities

        1.5.2 Market Risk

        1.5.3 Market Driving Force

2 Manufacturers Profiles

    2.1 AstraZeneca

        2.1.1 Business Overview

        2.1.2 Dyslipidemia Drugs Type and Applications

            2.1.2.1 Product A

            2.1.2.2 Product B

        2.1.3 AstraZeneca Dyslipidemia Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

    2.2 Merck

        2.2.1 Business Overview

        2.2.2 Dyslipidemia Drugs Type and Applications

            2.2.2.1 Product A

            2.2.2.2 Product B

        2.2.3 Merck Dyslipidemia Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

    2.3 Pfizer

        2.3.1 Business Overview

        2.3.2 Dyslipidemia Drugs Type and Applications

            2.3.2.1 Product A

            2.3.2.2 Product B

        2.3.3 Pfizer Dyslipidemia Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

    2.4 Sanofi

        2.4.1 Business Overview

        2.4.2 Dyslipidemia Drugs Type and Applications

            2.4.2.1 Product A

            2.4.2.2 Product B

        2.4.3 Sanofi Dyslipidemia Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

    2.5 Alnylam Pharmaceuticals

        2.5.1 Business Overview

        2.5.2 Dyslipidemia Drugs Type and Applications

            2.5.2.1 Product A

            2.5.2.2 Product B

        2.5.3 Alnylam Pharmaceuticals Dyslipidemia Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

    2.6 Amarin Corporation

        2.6.1 Business Overview

        2.6.2 Dyslipidemia Drugs Type and Applications

            2.6.2.1 Product A

            2.6.2.2 Product B

        2.6.3 Amarin Corporation Dyslipidemia Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

    2.7 Amgen

        2.7.1 Business Overview

        2.7.2 Dyslipidemia Drugs Type and Applications

            2.7.2.1 Product A

            2.7.2.2 Product B

        2.7.3 Amgen Dyslipidemia Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

    2.8 Bristol-Myers Squibb

        2.8.1 Business Overview

        2.8.2 Dyslipidemia Drugs Type and Applications

            2.8.2.1 Product A

            2.8.2.2 Product B

        2.8.3 Bristol-Myers Squibb Dyslipidemia Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

    2.9 Catabasis Pharmaceuticals

        2.9.1 Business Overview

        2.9.2 Dyslipidemia Drugs Type and Applications

            2.9.2.1 Product A

            2.9.2.2 Product B

        2.9.3 Catabasis Pharmaceuticals Dyslipidemia Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

    2.10 Cerenis

        2.10.1 Business Overview

        2.10.2 Dyslipidemia Drugs Type and Applications

            2.10.2.1 Product A

            2.10.2.2 Product B

        2.10.3 Cerenis Dyslipidemia Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

    2.11 Cipla

        2.11.1 Business Overview

        2.11.2 Dyslipidemia Drugs Type and Applications

            2.11.2.1 Product A

            2.11.2.2 Product B

        2.11.3 Cipla Dyslipidemia Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

    2.12 CJ HealthCare

        2.12.1 Business Overview

        2.12.2 Dyslipidemia Drugs Type and Applications

            2.12.2.1 Product A

            2.12.2.2 Product B

        2.12.3 CJ HealthCare Dyslipidemia Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

    2.13 CKD Bio

        2.13.1 Business Overview

        2.13.2 Dyslipidemia Drugs Type and Applications

            2.13.2.1 Product A

            2.13.2.2 Product B

        2.13.3 CKD Bio Dyslipidemia Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

    2.14 Daewoong Pharmaceutical

        2.14.1 Business Overview

        2.14.2 Dyslipidemia Drugs Type and Applications

            2.14.2.1 Product A

            2.14.2.2 Product B

        2.14.3 Daewoong Pharmaceutical Dyslipidemia Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

    2.15 Daiichi Sankyo

        2.15.1 Business Overview

        2.15.2 Dyslipidemia Drugs Type and Applications

            2.15.2.1 Product A

            2.15.2.2 Product B

        2.15.3 Daiichi Sankyo Dyslipidemia Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

    2.16 Eli Lilly

        2.16.1 Business Overview

        2.16.2 Dyslipidemia Drugs Type and Applications

            2.16.2.1 Product A

            2.16.2.2 Product B

        2.16.3 Eli Lilly Dyslipidemia Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

    2.17 Esperion Therapeutics

        2.17.1 Business Overview

        2.17.2 Dyslipidemia Drugs Type and Applications

            2.17.2.1 Product A

            2.17.2.2 Product B

        2.17.3 Esperion Therapeutics Dyslipidemia Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

    2.18 GlaxoSmithKline

        2.18.1 Business Overview

        2.18.2 Dyslipidemia Drugs Type and Applications

            2.18.2.1 Product A

            2.18.2.2 Product B

        2.18.3 GlaxoSmithKline Dyslipidemia Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

    2.19 JW Pharmaceuticals

        2.19.1 Business Overview

        2.19.2 Dyslipidemia Drugs Type and Applications

            2.19.2.1 Product A

            2.19.2.2 Product B

        2.19.3 JW Pharmaceuticals Dyslipidemia Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

    2.20 Kadmon Pharmaceuticals

        2.20.1 Business Overview

        2.20.2 Dyslipidemia Drugs Type and Applications

            2.20.2.1 Product A

            2.20.2.2 Product B

        2.20.3 Kadmon Pharmaceuticals Dyslipidemia Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

    2.21 Lupin Pharmaceuticals

        2.21.1 Business Overview

        2.2.2 Dyslipidemia Drugs Type and Applications

            2.21.2.1 Product A

            2.21.2.2 Product B

        2.21.3 Lupin Pharmaceuticals Dyslipidemia Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

3 Global Dyslipidemia Drugs Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)

    3.1 Global Dyslipidemia Drugs Sales and Market Share by Manufacturer (2016-2017)

    3.2 Global Dyslipidemia Drugs Revenue and Market Share by Manufacturer (2016-2017)

    3.3 Market Concentration Rate

        3.3.1 Top 3 Dyslipidemia Drugs Manufacturer Market Share in 2017

        3.3.2 Top 6 Dyslipidemia Drugs Manufacturer Market Share in 2017

    3.4 Market Competition Trend

4 Global Dyslipidemia Drugs Market Analysis by Regions

    4.1 Global Dyslipidemia Drugs Sales, Revenue and Market Share by Regions

        4.1.1 Global Dyslipidemia Drugs Sales and Market Share by Regions (2013-2018)

        4.1.2 Global Dyslipidemia Drugs Revenue and Market Share by Regions (2013-2018)

    4.2 North America Dyslipidemia Drugs  Sales and Growth Rate (2013-2018)

    4.3 Europe Dyslipidemia Drugs  Sales and Growth Rate (2013-2018)

    4.4 Asia-Pacific Dyslipidemia Drugs  Sales and Growth Rate (2013-2018)

    4.5 South America Dyslipidemia Drugs  Sales and Growth Rate (2013-2018)

    4.6 Middle East and Africa Dyslipidemia Drugs  Sales and Growth Rate (2013-2018)

5 North America Dyslipidemia Drugs by Countries

    5.1 North America Dyslipidemia Drugs Sales, Revenue and Market Share by Countries

        5.1.1 North America Dyslipidemia Drugs Sales and Market Share by Countries (2013-2018)

        5.1.2 North America Dyslipidemia Drugs Revenue and Market Share by Countries (2013-2018)

    5.2 United States Dyslipidemia Drugs Sales and Growth Rate (2013-2018)

    5.3 Canada Dyslipidemia Drugs Sales and Growth Rate (2013-2018)

    5.4 Mexico Dyslipidemia Drugs Sales and Growth Rate (2013-2018)

6 Europe Dyslipidemia Drugs by Countries

    6.1 Europe Dyslipidemia Drugs Sales, Revenue and Market Share by Countries

        6.1.1 Europe Dyslipidemia Drugs Sales and Market Share by Countries (2013-2018)

        6.1.2 Europe Dyslipidemia Drugs Revenue and Market Share by Countries (2013-2018)

    6.2 Germany Dyslipidemia Drugs Sales and Growth Rate (2013-2018)

    6.3 UK Dyslipidemia Drugs Sales and Growth Rate (2013-2018)

    6.4 France Dyslipidemia Drugs Sales and Growth Rate (2013-2018)

    6.5 Russia Dyslipidemia Drugs Sales and Growth Rate (2013-2018)

    6.6 Italy Dyslipidemia Drugs Sales and Growth Rate (2013-2018)

7 Asia-Pacific Dyslipidemia Drugs by Countries

    7.1 Asia-Pacific Dyslipidemia Drugs Sales, Revenue and Market Share by Countries

        7.1.1 Asia-Pacific Dyslipidemia Drugs Sales and Market Share by Countries (2013-2018)

        7.1.2 Asia-Pacific Dyslipidemia Drugs Revenue and Market Share by Countries (2013-2018)

    7.2 China Dyslipidemia Drugs Sales and Growth Rate (2013-2018)

    7.3 Japan Dyslipidemia Drugs Sales and Growth Rate (2013-2018)

    7.4 Korea Dyslipidemia Drugs Sales and Growth Rate (2013-2018)

    7.5 India Dyslipidemia Drugs Sales and Growth Rate (2013-2018)

    7.6 Southeast Asia Dyslipidemia Drugs Sales and Growth Rate (2013-2018)

8 South America Dyslipidemia Drugs by Countries

    8.1 South America Dyslipidemia Drugs Sales, Revenue and Market Share by Countries

        8.1.1 South America Dyslipidemia Drugs Sales and Market Share by Countries (2013-2018)

        8.1.2 South America Dyslipidemia Drugs Revenue and Market Share by Countries (2013-2018)

    8.2 Brazil Dyslipidemia Drugs Sales and Growth Rate (2013-2018)

    8.3 Argentina Dyslipidemia Drugs Sales and Growth Rate (2013-2018)

    8.4 Colombia Dyslipidemia Drugs Sales and Growth Rate (2013-2018)

9 Middle East and Africa Dyslipidemia Drugs by Countries

    9.1 Middle East and Africa Dyslipidemia Drugs Sales, Revenue and Market Share by Countries

        9.1.1 Middle East and Africa Dyslipidemia Drugs Sales and Market Share by Countries (2013-2018)

        9.1.2 Middle East and Africa Dyslipidemia Drugs Revenue and Market Share by Countries (2013-2018)

    9.2 Saudi Arabia Dyslipidemia Drugs Sales and Growth Rate (2013-2018)

    9.3 UAE Dyslipidemia Drugs Sales and Growth Rate (2013-2018)

    9.4 Egypt Dyslipidemia Drugs Sales and Growth Rate (2013-2018)

    9.5 Nigeria Dyslipidemia Drugs Sales and Growth Rate (2013-2018)

    9.6 South Africa Dyslipidemia Drugs Sales and Growth Rate (2013-2018)

10 Global Dyslipidemia Drugs Market Segment by Type

    10.1 Global Dyslipidemia Drugs Sales, Revenue and Market Share by Type (2013-2018)

        10.1.1 Global Dyslipidemia Drugs Sales and Market Share by Type (2013-2018)

        10.1.2 Global Dyslipidemia Drugs Revenue and Market Share by Type (2013-2018)

    10.2 Statins Sales Growth and Price

        10.2.1 Global Statins Sales Growth (2013-2018)

        10.2.2 Global Statins Price (2013-2018)

    10.3 Cholesterol absorption inhibitors Sales Growth and Price

        10.3.1 Global Cholesterol absorption inhibitors Sales Growth (2013-2018)

        10.3.2 Global Cholesterol absorption inhibitors Price (2013-2018)

    10.4 Dyslipidemia injectable Sales Growth and Price

        10.4.1 Global Dyslipidemia injectable Sales Growth (2013-2018)

        10.4.2 Global Dyslipidemia injectable Price (2013-2018)

11 Global Dyslipidemia Drugs Market Segment by Application

    11.1 Global Dyslipidemia Drugs Sales Market Share by Application (2013-2018)

    11.2 Hospitals and Clinics Sales Growth (2013-2018)

    11.3 Medical Laboratories Sales Growth (2013-2018)

    11.4 Drug Stores Sales Growth (2013-2018)

    11.5 Others Sales Growth (2013-2018)

12 Dyslipidemia Drugs Market Forecast (2018-2023)

    12.1 Global Dyslipidemia Drugs Sales, Revenue and Growth Rate (2018-2023)

    12.2 Dyslipidemia Drugs Market Forecast by Regions (2018-2023)

        12.2.1 North America Dyslipidemia Drugs Market Forecast (2018-2023)

        12.2.2 Europe Dyslipidemia Drugs Market Forecast (2018-2023)

        12.2.3 Asia-Pacific Dyslipidemia Drugs Market Forecast (2018-2023)

        12.2.4 South America Dyslipidemia Drugs Market Forecast (2018-2023)

        12.2.5 Middle East and Africa Dyslipidemia Drugs Market Forecast (2018-2023)

    12.3 Dyslipidemia Drugs Market Forecast by Type (2018-2023)

        12.3.1 Global Dyslipidemia Drugs Sales Forecast by Type (2018-2023)

        12.3.2 Global Dyslipidemia Drugs Market Share Forecast by Type (2018-2023)

    12.4 Dyslipidemia Drugs Market Forecast by Application (2018-2023)

        12.4.1 Global Dyslipidemia Drugs Sales Forecast by Application (2018-2023)

        12.4.2 Global Dyslipidemia Drugs Market Share Forecast by Application (2018-2023)

13 Sales Channel, Distributors, Traders and Dealers

    13.1 Sales Channel

        13.1.1 Direct Marketing

        13.1.2 Indirect Marketing

        13.1.3 Marketing Channel Future Trend

    13.2 Distributors, Traders and Dealers

14 Research Findings and Conclusion

15 Appendix

    15.1 Methodology

    15.2 Data Source


                        
            

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode
Single User | $(USD)3480 View Pricing